Sight Sciences earnings calendar and glaucoma focus, shares on Nasdaq in medtech peer group

Sight Sciences prepares for its next earnings update with glaucoma and dry eye devices at the core of its business. The medtech company trades on Nasdaq alongside peers in ophthalmology.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 16:36.

Sight Sciences Inc (US8177721062) is a US-based ophthalmic medical technology company whose shares trade on Nasdaq under the ticker SGHT, focusing on surgical and nonsurgical devices for glaucoma and dry eye disease. The company is in the post-2024-results period and prepares for its next quarterly update, with the last detailed guidance and strategic comments given in its 2024 earnings materials and subsequent investor presentations.

Business position and recent results

Sight Sciences reported its most recent full-year and quarterly financial figures previously via its investor relations site, including revenue development and operating losses that are typical for growth-focused medtech companies. The company focuses on commercializing its OMNI Surgical System and TearCare technology, emphasizing physician adoption, reimbursement pathways, and clinical data in the United States and selected international markets.

The company has highlighted in past presentations that the OMNI device targets minimally invasive glaucoma surgery procedures, while TearCare addresses dry eye disease through localized heat and expression of the meibomian glands. These segments place the business structurally alongside ophthalmology peers such as Glaukos and Alcon on Nasdaq, where specialized eye-care companies compete on technology innovation and clinical outcomes. Sight Sciences uses its investor days and quarterly calls to describe clinician feedback, usage patterns, and the expansion of its sales force in the US ophthalmology market.

Analyst coverage and market perception

Analyst coverage of Sight Sciences has been concentrated among US healthcare specialists following its listing on Nasdaq, with research notes in 2024 and 2025 discussing revenue growth rates, cash burn, and the timing of potential breakeven. Coverage typically compares the company to glaucoma and dry eye peers, examining how its product adoption, pricing, and reimbursement trends align with other ophthalmic device makers listed in the US.

Market commentary from healthcare-focused investment banks and independent research providers has underscored the regulatory and reimbursement landscape as a key factor for Sight Sciences, given that its devices rely on physician uptake and payer acceptance. Reports regularly monitor Medicare coding developments and private-insurance reimbursement decisions, as these can influence utilization rates for procedures involving the OMNI system and TearCare. The company’s communications and filings aim to inform investors about how changes in billing codes, clinical guidelines, and hospital purchasing decisions can affect revenue visibility and margin progression.

The product behind the stock

Sight Sciences generates revenue primarily by selling medical devices and related accessories that support minimally invasive procedures for glaucoma and treatments for dry eye disease. Its OMNI Surgical System and TearCare platform are used by ophthalmologists and optometrists in eye-care clinics and surgical centers.

The listing in brief

Sight Sciences shares trade on Nasdaq in US dollars under the ticker SGHT, reflecting investor sentiment toward its glaucoma and dry eye device portfolio and placing the company in the US medtech peer group.

Sight Sciences at a glance

• Company: Sight Sciences Inc
• ISIN: US8177721062
• WKN:
• Ticker: SGHT
• Trading venue: Nasdaq
• Price (as of 2026-06-25, 14:30): 0.00 USD
• Market cap: 0.00 USD (as of 2026-06-25)
• Sector / industry: Health Care Equipment
• Index membership:
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.